BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 09, 2004
 |  BioCentury  |  Product Development

The other way around EGF

In the late 1980s, when Cuban scientists began developing active and passive immunotherapies against epidermal growth factor (EGF) and its receptor, virtually all other efforts were targeting EGFr rather than the growth factor itself. Of the five major products on the market or in late- stage clinical trials, all are focused on EGFr, by inhibiting either EGFr signaling or the tyrosine kinase activity of EGFr. The Cubans are targeting EGF itself via a therapeutic vaccine, SAI-EGF (specific active immunotherapy EGF), which triggers the immune system to develop antibodies against EGF.

As researchers have looked at the Cuban data, companies have taken an interest. First was Canada's YM BioSciences Inc., which in 1995 took a license to SAI-EG, although it later gave back rights as part of a refocusing. Earlier this year, Biocon Ltd. obtained rights covering the Indian sub-continent through Biocon Biopharmaceuticals, its Indian joint venture with the Cuban Centre of Molecular Immunology S.A. (CIMAB)(see BioCentury, June 28).

A U.S. company has finally worked through the political tangle to get a stake in the...

Read the full 865 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >